In the United Kingdom, cannabis is the most commonly used illicit drug, and 7.4% of adults aged 16 to 59 claim to have used the drug in the past year (Office for National Statistics, 202). In an interview with The BMJ, he warned: “The government should see this as a possible time bomb. Thank you for your interest in spreading the word about The BMJ. In addition, the recruitment of participants from two different sources, a medical cannabis clinic for a patient population and social media for a recreational cannabis group, can also be a source of selection bias.
In addition, MCUs are affected by chronic health problems that are likely to be affected by comorbid sleep disorders, and data from the UK Medical Cannabis Registry suggest that these people experience self-reported improvements in sleep quality after starting treatment with CBMPs (Olsson et al. CBMP, cannabis-based medications; RCU, recreational cannabis users; MCU, medical cannabis users; PTSD, post-traumatic stress disorder; CMMQ, comprehensive questionnaire on marijuana motives; PCL-5, the PTSD checklist; CES-D, depression scale from the Center for Epidemiological Studies; STAI, state anxiety inventory. Specifically, the study aimed to analyze the differences between RCUs and MCUs with respect to their mental health and their motives for using cannabis, as well as individual differences, including the age and frequency of cannabis use, as well as the consumption of caffeine, alcohol and tobacco. Cannabis users currently living in the United Kingdom were invited to participate in the study, recruiting staff through social media for intensive care units or from Sapphire Medical Clinics for Sapphire medical monitoring units.
Overall, the current study provides a basis for future research on recreational and medical cannabis use in the UK United. The results showed differences in age, frequency of cannabis use, state of anxiety, and reasons for cannabis use between the two groups. While a significant difference between the two groups is that MCUs are supposed to use cannabis primarily to alleviate the symptoms of an underlying condition, it's also possible that UCRs also access cannabis to self-medicate at different levels. These findings further support the need to develop a clear policy position on the use of medical and recreational cannabis in the UK.
As the popularity of cannabis increases around the world, and especially the use of CBMPs, this type of research will promote a deeper and more substantial understanding of the risks and benefits associated with using cannabis for recreational purposes. and doctors. The main objective of the current study was to compare individual differences between RCUs and MCUs in the United Kingdom to investigate possible motivations for consumption that could reflect the overlap or divergence between cannabis users from two different groups. Taking into account substance use before completing the survey, there were only significant differences in cannabis use (p = 0.00 (see figure 2; the table), since MCUs had a higher frequency of cannabis use 24 hours before the survey (n = 71; 88.75%) than RCUs (n = 53; 66.25%; p 0.050).
